JP2014519524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519524A5 JP2014519524A5 JP2014515918A JP2014515918A JP2014519524A5 JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5 JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- seq
- heavy chain
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005614 monoclonal antibodies Human genes 0.000 claims 16
- 108010045030 monoclonal antibodies Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 201000004681 psoriasis Diseases 0.000 claims 5
- 102100014586 SELPLG Human genes 0.000 claims 4
- 101710023851 SELPLG Proteins 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000004526 Exfoliative Dermatitis Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001185 psoriatic Effects 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (17)
- ヒトPSGL−1に免疫特異的に結合するモノクローナル抗体であって、
(i)配列番号3のアミノ酸配列を含む可変軽(「VL」)鎖領域;
(ii)配列番号4のアミノ酸配列を含む可変重(「VH」)鎖領域を含む重鎖;および
(iii)EUインデックスの番号付けによる重鎖のアミノ酸228において、セリンからプロリンへの置換を含む、ヒトIgG4定常領域;
を含む、前記モノクローナル抗体。 - ヒトPSGL−1に免疫特異的に結合するモノクローナル抗体であって、
(i)配列番号1のアミノ酸配列を含む軽鎖;および
(ii)配列番号2のアミノ酸配列を含む重鎖;
を含む、前記モノクローナル抗体。 - ヒトPSGL−1に免疫特異的に結合するモノクローナル抗体であって、
(i)配列番号2からなる重鎖;および
(ii)配列番号1からなる軽鎖;
を含む、前記モノクローナル抗体。 - ヒトPSGL−1に免疫特異的に結合し、かつ
(i)配列番号8、9、および10を含むVH鎖領域;および
(ii)EUインデックスの番号付けによる重鎖のアミノ酸228において、セリンからプロリンへのアミノ酸置換を含む、ヒトIgG4重鎖定常領域;
を含む重鎖を含む、モノクローナル抗体。 - モノクローナル抗体が、配列番号5、6、および7を含むVL鎖領域を含む軽鎖をさらに含む、請求項4に記載のモノクローナル抗体。
- 抗体が精製されている、請求項1〜5のいずれか一項に記載のモノクローナル抗体。
- 請求項1〜6のいずれか一項に記載のモノクローナル抗体および薬学的に許容し得る担体を含む、医薬組成物。
- モノクローナル抗体が精製されている、請求項7に記載の医薬組成物。
- 配列番号2を含む、抗体重鎖。
- 請求項1〜6のいずれか一項に記載のモノクローナル抗体を含む第1容器を含む、キット。
- 請求項1〜6のいずれか一項に記載のモノクローナル抗体を含む、注入装置。
- 注入装置が注射器である、請求項11に記載の注入装置。
- 治療有効量の請求項1〜6のいずれか一項に記載のモノクローナル抗体または請求項7もしくは8に記載の医薬組成物を含む、炎症性障害を処置するための医薬組成物。
- 炎症性障害が自己免疫疾患である、請求項13に記載の医薬組成物。
- 炎症性障害が、乾癬、尋常性乾癬、慢性尋常性乾癬、滴状乾癬、逆位乾癬、膿疱性乾癬、乾癬性紅皮症、乾癬性関節炎、関節リウマチ、クローン病、強直性脊椎炎、または糖尿病である、請求項13または14に記載の医薬組成物。
- 治療有効量の請求項1〜6のいずれか一項に記載のモノクローナル抗体または請求項7もしくは8に記載の医薬組成物を含む、移植片対宿主病および移植拒絶反応を処置するための医薬組成物。
- 移植が、骨髄移植、肝移植、腎移植、または、任意の器官または組織の移植を含む、請求項16に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161496249P | 2011-06-13 | 2011-06-13 | |
US61/496,249 | 2011-06-13 | ||
PCT/US2012/042068 WO2012174001A1 (en) | 2011-06-13 | 2012-06-12 | Anti-psgl-1 antibodies and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014519524A JP2014519524A (ja) | 2014-08-14 |
JP2014519524A5 true JP2014519524A5 (ja) | 2015-07-30 |
JP6180408B2 JP6180408B2 (ja) | 2017-08-16 |
Family
ID=47357432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014515918A Active JP6180408B2 (ja) | 2011-06-13 | 2012-06-12 | 抗psgl−1抗体およびその使用 |
Country Status (20)
Country | Link |
---|---|
US (4) | US20130209449A9 (ja) |
EP (2) | EP2718325A4 (ja) |
JP (1) | JP6180408B2 (ja) |
KR (1) | KR102103036B1 (ja) |
CN (3) | CN108892726A (ja) |
AU (1) | AU2012271845B2 (ja) |
BR (1) | BR112013031892A2 (ja) |
CA (1) | CA2838952C (ja) |
CL (1) | CL2013003570A1 (ja) |
CO (1) | CO6940376A2 (ja) |
EC (1) | ECSP14013132A (ja) |
IL (2) | IL229844B (ja) |
MX (1) | MX358447B (ja) |
NZ (1) | NZ619524A (ja) |
RU (1) | RU2650817C2 (ja) |
SG (1) | SG10201604767TA (ja) |
TW (1) | TWI643872B (ja) |
UA (1) | UA114712C2 (ja) |
WO (1) | WO2012174001A1 (ja) |
ZA (1) | ZA201400209B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
AR048840A1 (es) | 2004-05-11 | 2006-05-31 | Boehringer Ingelheim Int | Epitopes inductores de la muerte de las celulas t |
CA2838952C (en) | 2011-06-13 | 2020-11-24 | Stefan Bassarab | Anti-psgl-1 antibodies and uses thereof |
ES2877171T3 (es) * | 2014-07-08 | 2021-11-16 | Sanford Burnham Med Res Inst | Moduladores de PSGL-1 y usos de los mismos |
RU2766000C2 (ru) * | 2016-01-08 | 2022-02-07 | АльтруБио Инк. | Четырехвалентные антитела к psgl-1 и их применения |
WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
TWI788321B (zh) * | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
EP3595720A4 (en) | 2017-03-14 | 2021-05-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT AN ACID PH |
EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
AU2022394559A1 (en) * | 2021-11-17 | 2024-05-09 | Altrubio Inc. | Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers |
WO2024057232A1 (en) * | 2022-09-13 | 2024-03-21 | Tetherex Pharmaceuticals Corporation | Antibodies, compositions, and methods of treatment |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
CA2130173A1 (en) | 1992-03-17 | 1993-09-30 | Norman Hardman | Genetically engineered antibodies |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5710123A (en) | 1992-12-18 | 1998-01-20 | Centocor, Inc. | Peptide inhibitors of selectin binding |
EP0689599B1 (en) | 1993-01-25 | 1998-12-09 | Dana-Farber Cancer Institute, Inc. | Chimeric selectins by exchange of domains - uses thereof |
WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
JPH11510543A (ja) | 1995-08-03 | 1999-09-14 | ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ | ペプチド及びセレクチン介在炎症のo−グリカン阻害剤 |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
AU774419C (en) | 1998-10-30 | 2005-03-03 | Genetics Institute, Llc | Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
AU6173501A (en) | 2000-05-19 | 2001-12-03 | Blood Res Center | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
EP1325123A4 (en) | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS |
US20040002450A1 (en) | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
CZ20031982A3 (cs) | 2000-12-29 | 2004-09-15 | Bio-Technology General Corp. | Izolované molekuly zahrnující epitopy obsahující sulfatované sloučeniny, protilátky proti takovým epitopům a jejich použití |
CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
PL374439A1 (en) | 2002-07-01 | 2005-10-17 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
RU2006102571A (ru) | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Специфические антитела человека |
KR101200188B1 (ko) * | 2003-12-25 | 2012-11-13 | 교와 핫꼬 기린 가부시키가이샤 | 항 cd40 항체의 변이체 |
JP5150103B2 (ja) * | 2004-02-13 | 2013-02-20 | イミューノメディクス、インコーポレイテッド | 組み換え細胞毒性RNAseを含む融合タンパク質 |
SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
AR048840A1 (es) | 2004-05-11 | 2006-05-31 | Boehringer Ingelheim Int | Epitopes inductores de la muerte de las celulas t |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
MX2009000476A (es) * | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
UA102994C2 (ru) * | 2007-03-22 | 2013-09-10 | Дженентек, Инк. | АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ |
NZ614857A (en) * | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
CN101801407B (zh) | 2007-06-05 | 2013-12-18 | 耶鲁大学 | 受体酪氨酸激酶抑制剂及其使用方法 |
JP2010537985A (ja) * | 2007-08-28 | 2010-12-09 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | 抗igf−1r抗体およびその使用 |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
US20110086366A1 (en) * | 2008-02-22 | 2011-04-14 | Genmab A/S | Methods for assessing the risk of adverse events upon treatment with igg4 antibodies |
WO2009140623A2 (en) * | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
US20100233157A1 (en) * | 2009-03-12 | 2010-09-16 | Osorio Lyda M | Human antibodies against human fas and their use |
WO2011014438A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
CA2838952C (en) | 2011-06-13 | 2020-11-24 | Stefan Bassarab | Anti-psgl-1 antibodies and uses thereof |
BR112016029588A2 (pt) | 2014-06-20 | 2017-08-22 | Abgenomics Int Inc | conjugados de anticorpo-fármaco para her2 |
-
2012
- 2012-06-12 CA CA2838952A patent/CA2838952C/en active Active
- 2012-06-12 EP EP12799966.2A patent/EP2718325A4/en not_active Ceased
- 2012-06-12 CN CN201810722769.2A patent/CN108892726A/zh active Pending
- 2012-06-12 NZ NZ619524A patent/NZ619524A/en unknown
- 2012-06-12 MX MX2013014814A patent/MX358447B/es active IP Right Grant
- 2012-06-12 WO PCT/US2012/042068 patent/WO2012174001A1/en active Application Filing
- 2012-06-12 SG SG10201604767TA patent/SG10201604767TA/en unknown
- 2012-06-12 CN CN202211394154.4A patent/CN116063522A/zh active Pending
- 2012-06-12 EP EP21168455.0A patent/EP3925978A1/en active Pending
- 2012-06-12 RU RU2013158083A patent/RU2650817C2/ru active
- 2012-06-12 KR KR1020147000603A patent/KR102103036B1/ko active IP Right Grant
- 2012-06-12 AU AU2012271845A patent/AU2012271845B2/en active Active
- 2012-06-12 UA UAA201314798A patent/UA114712C2/uk unknown
- 2012-06-12 US US13/494,398 patent/US20130209449A9/en not_active Abandoned
- 2012-06-12 JP JP2014515918A patent/JP6180408B2/ja active Active
- 2012-06-12 BR BR112013031892A patent/BR112013031892A2/pt not_active Application Discontinuation
- 2012-06-12 CN CN201280039482.0A patent/CN103732626A/zh active Pending
- 2012-06-13 TW TW101121146A patent/TWI643872B/zh active
-
2013
- 2013-04-17 US US13/865,085 patent/US20130251708A1/en not_active Abandoned
- 2013-12-08 IL IL229844A patent/IL229844B/en unknown
- 2013-12-12 CL CL2013003570A patent/CL2013003570A1/es unknown
-
2014
- 2014-01-09 ZA ZA2014/00209A patent/ZA201400209B/en unknown
- 2014-01-13 EC ECSP14013132 patent/ECSP14013132A/es unknown
- 2014-01-13 CO CO14004726A patent/CO6940376A2/es unknown
-
2021
- 2021-08-30 US US17/460,883 patent/US11897964B2/en active Active
- 2021-10-14 IL IL287270A patent/IL287270A/en unknown
-
2023
- 2023-12-26 US US18/396,607 patent/US20240124604A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014519524A5 (ja) | ||
RU2013158083A (ru) | Анти-psgl-1-антитела и их применение | |
HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
JP2014505463A5 (ja) | ||
HRP20200070T1 (hr) | Humana antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3) i njihove primjene | |
RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
RU2019119442A (ru) | Новый коньюгат аманитина | |
CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
JP2010500370A5 (ja) | ||
JP2013545438A5 (ja) | ||
JP2012070740A5 (ja) | ||
RU2017102193A (ru) | Конструкции полиспецифических антител | |
SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
DK2066349T3 (da) | Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme | |
JP2015535828A5 (ja) | ||
JP2010526028A5 (ja) | ||
HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
IN2014CN03936A (ja) | ||
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
RU2016151265A (ru) | Антитела, направленные на cd127 |